Novel Coronavirus Infection and Reproductive Function

Sponsor
Jinling Hospital, China (Other)
Overall Status
Recruiting
CT.gov ID
NCT05685992
Collaborator
(none)
400
3
12.4
133.3
10.8

Study Details

Study Description

Brief Summary

This study aims to observe the impact of COVID-19 infection on the reproductive function and assisted pregnancy outcome of infertile couples undergoing assisted reproductive technology and to determine which factors are related to the clinical pregnancy rate. A multicenter, prospective, observational cohort study was adopted. Infertile couples who met the selection criteria were included in this study, the SAS anxiety self-rating scale was filled out, the basic situation was observed, and blood samples and related tissues were collected for testing. Relevant reproductive function, laboratory, clinical, and psychological indicators were collected, and the correlation between the above indicators and the outcome of the ART-related pregnancy were analyzed.

Condition or Disease Intervention/Treatment Phase
  • Other: no intervention

Detailed Description

In this multicenter, prospective, observational cohort study, we included infertile couples based on inclusion criteria. The couples were asked to fill in the SAS anxiety self-rating scale. Basic information about patients' vaccination status, symptoms related to viral infection, menstruation, sexual desire, and sexual function were obtained. Blood samples of couples were collected on the date of diagnosis, the start date of the fresh cycle during assisted reproductive technology treatment, the day of oocyte retrieval, the day of embryo transfer, the day of 14 days, 35 days after embryo transfer, and the day of 70 days of gestation. Follicular fluid, granulosa cells on the day of oocyte retrieval, and embryo culture fluid on the day of embryo transfer were collected. Blood samples and endometrial tissues were collected five days after oocyte retrieval. Blood samples from the menstrual period, endometrial transformation day, and embryo transfer day of the frozen embryo transfer cycle were also collected. Then C-reactive protein, erythrocyte sedimentation rate, procalcitonin and IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-α, VEGF, and other cytokines and chemokines were determined. In addition, fasting blood glucose, insulin, blood lipids, alpha-function, renin-angiotensinase, I-aldosterone, and other susceptibility indicators to COVID-19 infection were tested. Oxygen saturation, malondialdehyde (MDA), HO-1, and SOD oxidative stress indices of the fingertip pulse were determined. An endometrial receptivity gene chip and proteomics detected endometrial tissue. A panel kit for blood vessel and inflammation indicators detected the abortion decidua tissue. Reproductive function indices AMH, INHB, sex hormones, follicle retrieval rate, Gn days, total Gn, endometrial thickness, the incidence of OHSS, semen quality, oocyte maturation rate, fertilization rate, qualified embryo rate, blastocyst formation rate, and other laboratory indices of both men and women were collected. Assisted pregnancy outcome: clinical pregnancy rate, embryo implantation rate, early abortion rate, ongoing pregnancy rate, and other clinical indicators, as well as psychological indicators such as the SAS anxiety scale, were analyzed to determine the correlation between the above indicators and ART-related pregnancy outcome.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Effects and Underlying Mechanisms of Novel Coronavirus Infection on Reproductive Function and Assisted Pregnancy Outcome
Actual Study Start Date :
Jan 20, 2023
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Jan 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Infertile couples infected or not infected with COVID-19

Infertile couples infected or not infected with COVID-19 were included.This is an observational study with no interventions.

Other: no intervention
no intervention

Outcome Measures

Primary Outcome Measures

  1. Ongoing pregnancy rate [1 year]

    If the fetal sac, fetal bud, and primitive fetal heartbeat are found by vaginal B-ultrasound examination 55-65 days after embryo transfer, the diagnosis of ongoing pregnancy will be made.

Secondary Outcome Measures

  1. Clinical and laboratory indicators related to male and female reproductive function [1 year]

    AMH, INB, sex hormone, follicle output rate, Gn days, total Gn, endometrial thickness on the embryo transfer day, semen quality; Oocyte maturation rate, fertilization rate, high-level embryo rate, blastocyst formation rate

  2. Outcome indicators of assisted pregnancy [1 year]

    Embryo implantation rate, early abortion rate, ongoing pregnancy rate, incidence of OHSS

Other Outcome Measures

  1. Coagulation index [1 year]

    D-dimer

  2. Indicators of susceptibility to COVID-19 infection [1 year]

    blood lipid, blood sugar, insulinand thyroid function

  3. Oxidative stress index [1 year]

    fingertip pulse oxygen saturation

  4. SAS Anxiety Scale [1 year]

    SAS Anxiety Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 42 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with infertility
Exclusion Criteria:
  • Patients with contraindications to pregnancy or assisted reproductive technology

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department for Reproductive Medicine, Jinling Hospital Nanjing Jiangsu China
2 Department of Reproductive Medicine, Nantong Maternal and Child Health Care Hospital Nantong Jiangsu China
3 Department of Reproductive Medicine, Xuzhou Maternal and Child Health Care Hospital Xuzhou Jiangsu China

Sponsors and Collaborators

  • Jinling Hospital, China

Investigators

  • Study Chair: Bing Yao, PHD, Department of Reproductive Medicine, Jinling Hospital
  • Study Director: Li Chen, PHD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Xiaojie Huang, PHD, Department of Reproductive Medicine, Xuzhou Maternal and Child Health Care Hospital
  • Principal Investigator: Jiayi Ding, PHD, Department of Reproductive Medicine, Nantong Maternal and Child Health Care Hospital
  • Principal Investigator: Qin Sun, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Meiling Li, PHD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Cheng Zhou, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Xi Chen, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Yuming Feng, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Juanjuan Xu, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Haiyan Fu, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Cencen Wang, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Hong Zhang, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Lu Zheng, MD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Yuxiu Liu, PHD, Department of Critical Care Medicine, Jinling Hospital
  • Principal Investigator: Xiaofang Tan, MD, Department of Reproductive Medicine, Nantong Maternal and Child Health Care Hospital
  • Principal Investigator: Yunxia Zhu, MD, Department of Reproductive Medicine, Xuzhou Maternal and Child Health Care Hospital
  • Principal Investigator: Jueraitetibaike Kadiliya, PHD, Department of Reproductive Medicine, Jinling Hospital
  • Principal Investigator: Zhichan Zou, MD, Department of Reproductive Medicine, Jinling Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Bing Yao, Professor, Jinling Hospital, China
ClinicalTrials.gov Identifier:
NCT05685992
Other Study ID Numbers:
  • COVID-19 and reproduction
First Posted:
Jan 17, 2023
Last Update Posted:
Jan 31, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Bing Yao, Professor, Jinling Hospital, China
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2023